Company Overview and News
MannKind (MNKD) announced today via an 8-K SEC filing that the company has negotiated the terms of Deerfield debt again and as a result has issued 7,367,839 shares to handle some of the payment that was due on July 18th of this year. The company had $10,000,000 due and erased $7,000,000 of that obligation with this transaction. The other $3,000,000 has been deferred to August 31st of 2018. That amount can be paid with shares (at the option of Deerfield) at a price of $1.
RANCHO CUCAMONGA, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). To date, ANP has provided Active Pharmaceutical Ingredients (“APIs”) and starting materials specifically to Amphastar. After the expansion is completed, ANP intends to begin selling APIs both to Amphastar and externally around the world to expand its overall markets.
Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Allergan (AGN - Free Report) and Amphastar Pharmaceuticals (AMPH - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Anika Therapeutics (ANIK) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combination anti-inflammatory formula that combines hyaluronic acid (‘HA) with a steroid (triamcinolone hexacetonide). HA serves as a lubricant for arthritic joints.
NTLA CYAD AMGN ANIK PSTI CRSP SRPT MDWD CANF AMPH NVUS RSLS ALXN ALNA KALA CYAD CLBS PRTA PSTIW
RANCHO CUCAMONGA, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has granted approval of its abbreviated new drug application (“ANDA”) for Isoproterenol Hydrochloride Injection, USP 0.2mg/mL, 1mL and 0.2mg/mL, 5mL single dose vial. Isoproterenol Hydrochloride is indicated for multiple uses including for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy.
Arbor Realty Trust (ABR - Free Report) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ABR broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend.
AMPH ABR ABRN DB ABRN.CL ABR.PRB ABR.PRC ABR.PRA
MGM Resorts International (MGM - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for MGM broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
AMPH MGM DB
Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for AMPH broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
RANCHO CUCAMONGA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 5, 2018 at 3:00 p.m. Eastern Time in New York, NY.
RANCHO CUCAMONGA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) supplement for the manufacture of semi-purified heparin at the company’s subsidiary, Amphastar Nanjing Pharmaceuticals (“ANP”) and the manufacture of heparin sodium USP at the company’s subsidiary, International Medication Systems, Limited.
Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) is a specialty pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 36.5% downward over the last 30 days.
LSXMB BGCP BATRK FWONB LSXMA CRUS BATRR BGCA DY FWONA MRC AMPH BHVN FWONK BATRB LSXMK RWT BATRA
AAC Technologies Holdings Inc. (AACAY - Free Report) is an investment holding company. The Zacks Consensus Estimate for its current year earnings has been revised 6.1% downward over the last 30 days.
AMPH AHL.PRB AHL.PRC AHL.PRA AHL CERN AACAY AACAF AKAM AHL.PRD
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to AMPH / Amphastar Pharmaceuticals, Inc. on message board site Silicon Investor.
|A Camphouse cupboard - My Notes to me||APH: Amphenol Corporation|
|CFV - Camphor Ventures||Amphenol (APH) Turnaround or Takeover?|
as of ET